September 2026's Leading Growth Companies With Insider Backing
In the last week, the United States market has been flat, but over the past 12 months, it has seen a notable rise of 12%, with earnings forecasted to grow by 17% annually. In this environment, growth companies with high insider ownership can be particularly appealing as they often indicate confidence from those closest to the company's operations and potential.
Top 10 Growth Companies With High Insider Ownership In The United States
| Name | Insider Ownership | Earnings Growth |
| Uxin (UXIN) | 34.3% | 69.4% |
| Upstart Holdings (UPST) | 14.0% | 68.4% |
| Standard Nuclear (STDN) | 18.8% | 61.3% |
| Precigen (PGEN) | 11.7% | 55.4% |
| Nu Holdings (NU) | 22.8% | 21.7% |
| Karman Holdings (KRMN) | 14.4% | 56.2% |
| Himax Technologies (HIMX) | 29.2% | 70.2% |
| Dave (DAVE) | 16.7% | 23.6% |
| Carlyle Group (CG) | 27.4% | 22% |
| Almonty Industries (ALM) | 10.8% | 38% |
We'll examine a selection from our screener results.
BillionToOne (BLLN)
Simply Wall St Growth Rating: ★★★★★☆
Overview: BillionToOne, Inc. is a precision diagnostics company specializing in molecular diagnostics with a market cap of $4.99 billion.
Operations: The company generates revenue from its Medical Labs & Research segment, totaling $397.41 million.
Insider Ownership: 10.6%
Earnings Growth Forecast: 33.4% p.a.
BillionToOne's growth trajectory is supported by its innovative product launches and strong financial performance. Recent introductions like Northstar Origin and expansions in the Northstar Select panel highlight its focus on addressing critical diagnostic challenges in oncology. The company's revenue is forecast to grow over 20% annually, outpacing the US market, with earnings expected to increase significantly. Despite high volatility in share price, BillionToOne remains a compelling growth story with robust insider ownership and strategic advancements in prenatal screening and oncology diagnostics.
- Click here and access our complete growth analysis report to understand the dynamics of BillionToOne.
- The analysis detailed in our BillionToOne valuation report hints at an inflated share price compared to its estimated value.
Precigen (PGEN)
Simply Wall St Growth Rating: ★★★★★★
Overview: Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases, with a market cap of $2.79 billion.
Operations: The company generates revenue from its Biotechnology (Startups) segment, amounting to $85.72 million.
Insider Ownership: 11.7%
Earnings Growth Forecast: 55.4% p.a.
Precigen's growth potential is underscored by its forecasted revenue increase of 34.8% annually, surpassing the US market average. Despite recent index exclusions, the company reported significant financial improvements with Q2 2026 revenue at US$54.98 million and a net income turnaround to US$20.07 million from a loss last year. While insider buying has been limited recently, insiders have sold more shares than bought over three months, indicating mixed sentiment amid expected profitability within three years.
- Dive into the specifics of Precigen here with our thorough growth forecast report.
- The valuation report we've compiled suggests that Precigen's current price could be inflated.
Daqo New Energy (DQ)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Daqo New Energy Corp. manufactures and sells polysilicon to photovoltaic product manufacturers in China, with a market cap of approximately $816.73 million.
Operations: The company's revenue is primarily derived from its polysilicon segment, amounting to $555.69 million.
Insider Ownership: 36.2%
Earnings Growth Forecast: 106.8% p.a.
Daqo New Energy is forecasted to achieve significant revenue growth of 37% annually, outpacing the US market. Despite recent exclusion from the FTSE All-World Index and ongoing net losses—US$81.15 million in Q2 2026—analysts anticipate profitability within three years, suggesting potential for recovery. The company trades significantly below its estimated fair value, indicating possible undervaluation. Recent financial results show declining sales but stable polysilicon production volumes, reflecting operational consistency amidst financial challenges.
- Take a closer look at Daqo New Energy's potential here in our earnings growth report.
- Our expertly prepared valuation report Daqo New Energy implies its share price may be lower than expected.
Taking Advantage
- Unlock our comprehensive list of 180 Fast Growing US Companies With High Insider Ownership by clicking here.
- Seeking Other Investments? The latest GPUs need a type of rare earth metal called Terbium and there are only 36 companies in the world exploring or producing it. Find the list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com